Advertisement
help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Niederhuber, J. E.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Niederhuber, J. E.
The Oncologist, Vol. 2, No. 5, 280–283, October 1997
© 1997 AlphaMed Press

Cancer Vaccines: The Molecular Basis for T Cell Killing of Tumor Cells

John E. Niederhuber

University of Wisconsin, Comprehensive Cancer Center, Madison, Wisconsin, USA

Correspondence: John E. Niederhuber, M.D., University of Wisconsin, Comprehensive Cancer Center, Room K6/614 Clinical Science Center, 600 Highland Avenue, Madison, Wisconsin 53792, USA. Telephone: 608-263-8610; Fax: 608-263-8613.

This issue of The Oncologist provides the reader with two important reviews on the subject of cancer vaccines. In these reviews, the authors address the rationale and biology supporting the use of immune-response enhancing cancer vaccines in human clinical trials. Although the titles of the manuscripts are similar, the subject is large and these two well-known research groups provide unique perspectives with little overlap of content. As with so many areas of human biology and disease, the field of tumor immunology has benefited tremendously by the application of molecular genetic technologies to the study of the critical mechanisms of antigen recognition, antigen processing and effector cell generation. This progress in elucidating the molecular events operative in the generation of an anti-tumor response justifies the translation of the many animal models of tumor vaccine therapy into clinical trials, especially for those tumors known to be unusually susceptible to immunotherapy.

As more and more information has been forthcoming regarding the generation of specific anti-tumor cytotoxic T lymphocytes (CTL) and how the population of these cells can be expanded, it has become increasingly important to understand the genetic mechanisms involved in the destruction of the targeted tumor cell [1, 2]. During the past two decades, very exciting progress has resulted from the observation that this cell-mediated destruction, as well as other methods of cell killing, including ionizing radiation, occur by signaling a pre-programmed path of senescence within the cell [3, 4].

The destruction of targeted cancer cells by antigen-specific, MHC-restricted CTL occurs by two independent effector pathways that induce genetically programmed cell death, termed apoptosis [5–12]. The first pathway involves the release (exocytosis) of granules by the CTL upon appropriate contact and antigenic recognition of the target cell. The second pathway is nonsecretory and requires the interaction of the CD95L molecule (Fas ligand) on the CTL with the CD95 (Fas) molecule present on the target tumor cell. As both pathways culminate in apoptotic cell death, it has been easy to speculate that the intracellular processes are common to both.

In the secretory pathway, granules disperse their contents into the intercellular space between the CTL and the cancer cell. The lymphocyte-specific granules release two principal proteins—perforin and serine protease(s) [6]. This mechanism of tumor cell destruction by CTL is often referred to as the perforin-based pathway because it is dependent on the presence of the pore-forming activity of perforin for the function of the serine protease, granzyme B [6, 8, 10, 13]. Perforin induces complement-like holes in the cancer cell membrane [14]. Perforin appears to accomplish this by polymerizing in the cell’s plasma membrane when ionized calcium is present [15–18]. It has been estimated that up to 20 perforin monomers are required to form a functional transmembrane tubular pore [19–21]. While these pores seriously damage the cell membrane, perforin by itself, even at high concentrations, is not capable of apoptosis, as it requires the presence of granzyme B. Similarly, granzyme B cannot by itself produce cell killing. It has been shown that granzyme B can enter the cytoplasm of the target cell without perforin being present, but requires perforin for activity and for translocation to the nucleus [22–25].



John E. Niederhuber, M.D.
Director
University of Wisconsin
Comprehensive Cancer Center

Granzyme B has some unique features. For example, its proteolytic activity is specific for aspartic acid in the P1 position [26–29]. This observation is important when it is placed in the context of activation of a second family of cellular proteases, the cysteine protease interleukin-1ß-converting enzyme (ICE) family [30, 31]. This family of proteases, called the caspase family, is involved in the process of apoptosis [32]. Caspase-1, interestingly, is a homologue of the CED-3 cell death gene first discovered in nematodes (Caenorhabditus elegans) [33]. Members of the caspase family identified to date (caspases 1-10) include: ICE, ICH-1, CPP32, ICE-2, ICErel-III, Mch2, Mch3, MACH, Mch6, and Mch4 [32].

Although the first "cell death" gene to be extensively characterized at the molecular level was the mammalian gene bcl-2, the discovery of a family of genes responsible for cell death in C. elegans served as a major stimulus for our current understanding of apoptosis [35–37]. Analysis of the C. elegans genes showed remarkable overall homology with the caspase family of genes in humans, providing an excellent model for study [34]. Specific mutants of the C. elegans genes demonstrated that apoptosis required activity of two genes, ced-3 and ced-4 [35]. The ced-3 gene encodes a cysteine protease with aspartic acid specificity for its activation and ced-4 appears to be essential for this activation [38–41]. Specifically, the ced-3 protein is present in its inactive form and is activated when its regulatory prodomain is cleaved at aspartic acid, permitting the active domain to assemble itself as a heteromeric protease [41, 42]. Initially, it was thought that granzyme B functioned to activate the ced-3-equivalent caspase-3, but more recent evidence suggests that granzyme B activates an upstream caspase called Apaf-1 similar to ced-4 in the C. elegans model [41–47].

While it has been frequently speculated that both the secretory (perforin-based) and nonsecretory (Fas) pathways of CTL-mediated target cell death share common downstream caspase activation events for the induction of apoptosis, this does not appear to be the case. Perhaps this should be expected, since both pathways have been preserved. In the Fas-based nonsecretory pathway, the FasL on the CTL cross-links with CD95 Fas on the target cell. Trimerization of CD95 occurs as a result of the cross-linking stimulus, causing an intracellular attraction of signaling molecules around the cytoplasmic tail of CD95 [25]. The CD95 cytoplasmic tail contains a "death domain" which interacts with a corresponding domain on a Fas-associated protein (FADD). The recruitment of FADD to the plasma membrane and its binding to the Fas tail activates FADD so that it can interact with caspase FLICE [40, 48, 49]. These interactions occur through specific motifs termed "death effector domains" found at the amino terminus of FLICE and the carboxyl terminus of FADD [50].

What is common to these two pathways is the ability to activate the caspase system which is ultimately responsible for nuclear fragmentation (implosion and endonuclease activation). Nuclear fragmentation is the oft-used hallmark of apoptotic cell death. Recent experiments, however, remind us that target-cell lysis is more complex and can certainly occur without nuclear damage. For example, Nakajima and colleagues showed that neither of the two CTL-induced apoptotic pathways require the presence of target cell nuclei for cell destruction [51]. Both secretory and nonsecretory paths are active in nuclear-free target cell preparations. Furthermore, when caspase-specific inhibitors such as peptide-based fluoromethyl ketones and baculovirus protein p53 were used in vitro, cell death occurred by the perforin-granzyme B pathway but not by the FasL-Fas path [52, 53].

This issue of The Oncologist provides the reader with two important reviews on the subject of cancer vaccines.

In these experiments, nuclear damage was effectively blocked for both secretory and nonsecretory pathways. This suggests that while CTL granular exocytosis-induced target cell lysis (estimated to account for approximately two-thirds of the destruction of target cells) can clearly activate the nuclear caspases, cell lysis can occur independent of the caspase system and without nuclear fragmentation. The downstream non-nuclear molecular targets for granzyme B remain to be identified. These experimental observations emphasize the need to recognize that apoptotic cell death has more than one intracellular process and, on occasion, occurs in the absence of activation of the caspase family of cell death genes.

If these are the genes and gene products functioning to effect apoptosis, are there specific molecules functioning as inhibitors of apoptosis? To answer this question, one needs only to look to certain viruses known to carry genes whose protein products are able to prevent the infected cell from dying so that the virus can replicate [54]. A family of proteins capable of inhibiting apoptosis has been identified in a number of {gamma}-herpes viruses and have been termed {gamma}-FLIPs for viral FLICE inhibitory proteins. These {gamma}-FLIP proteins can be shown to interact with FADD through the death-effector domains effectively blocking the interaction of FLICE and FADD in the intracellular signaling pathway induced by Fas stimulation [53]. Some of these viral anti-apoptotic genes resemble the bcl-2 gene, and this gene is similar to an anti-cell death gene ced-9 of C. elegans [37]. When the ced-9 protein is activated, it prevents the activation of ced-3 [54].

The development of strategies for generating effective numbers of antigen-specific CTL in an immune response against a tumor is a major goal of investigators hoping to add an anti-tumor immune response to a patient’s therapeutic options. As the two reviews in this issue of The Oncologist indicate, many recent advances hold considerable promise for reaching this goal. The mechanisms by which antigen-specific MHC-restricted CTL effectively cause tumor cell death are of potentially similar value, as they provide additional opportunities at the genetic level and protein function level by which the efficacy of the anti-tumor immune response can be further enhanced.


   REFERENCES
Top
 References
 

  1. Tschopp J, Nobholtz M. Perforin-mediated target cell lysis by cytolytic T lymphocytes. Annu Rev Immunol 1990;8:279–302.[Medline]
  2. Niederhuber JE, Boon T, Coulie PG et al. Immunology of the cancer cell-T lymphocyte responses, B lymphocyte responses. In: Abeloff MD, Armitage JO, Lichter AS et al., eds. Clinical Oncology. New York: Churchill Livingstone, 1995:89–126.
  3. Duke RC. In: Tornei LD, Cope FO eds. Apoptosis: The Molecular Basis of Cell Death. Apoptosis in cell-mediated immunity. New York: Cold Spring Harbor Laboratory Press, 1991:209–226.
  4. Kagi D, Ledermann B, Burki K et al. Molecular mechanisms of lymphocyte-mediated cytotoxicity and their role in immunological protection and pathogenesis in vivo. Annu Rev Immunol 1996;14:207–232.[Medline]
  5. Shi L, Kraut RP, Aebersold R et al. A natural killer cell granule protein that induces DNA fragmentation and apoptosis. J Exp Med 1992;175:553–566.[Abstract/Free Full Text]
  6. Heusel JW, Wesselschmidt RL, Shresta S et al. Cytotoxic lymphocytes require granzyme B for the rapid induction of DNA fragmentation and apoptosis in allogeneic target cells. Cell 1994;76:977–987.[Medline]
  7. Kaegi D, Vignaux F, Ledermann B et al. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 1994;265:528–530.[Abstract/Free Full Text]
  8. Kaegi D, Ledermann B, Buerki K et al. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 1994;369:31–37.[Medline]
  9. Kojima H, Shinohara N, Hanaoka S et al. Two distinct pathways of specific killing revealed by perforin mutant cytotoxic T lymphocytes. Immunity 1994;1:357–364.[Medline]
  10. Lowin B, Hahne M, Mattmann C et al. Cytolytic T-cell cytotoxicity is medicated through perforin and Fas lytic pathways. Nature 1994;370:650–652.[Medline]
  11. Rouvier M, Luciani MF, Golstein P. Fas involvement in Ca (2+)-independent T-cell mediated cytotoxicity. J Exp Med 1993;177:195–200.[Abstract/Free Full Text]
  12. Shi L, Kam CM, Powers JC. Purification of three cytotoxic lymphocyte granula serine proteases that induce apoptosis through distant substrate and target cell interactions. J Exp Med 1992;176:1521–1529.[Abstract/Free Full Text]
  13. Hudig D, Allison NJ, Pickett TM et al. The function of lymphocyte proteases. Inhibition and restoration of granule-mediated lysis with isocoumarin serine protease inhibitors. J Immunol 1991;147:1360–1368.[Abstract]
  14. Walsh CM, Matloubian M, Liu CC et al. Immune function in mice lacking the perforin gene. Proc Natl Acad Sci USA 1994;91:10854–10858.[Abstract/Free Full Text]
  15. Young JD-E, Cohn ZA, Podack ER. The ninth component of complement and the pore-forming protein (perforin 1) from cytotoxic T cells: structural, immunological and functional similarities. Science 1986;233:184–190.[Abstract/Free Full Text]
  16. Henkart PA, Millard PJ, Reynolds CW et al. Cytolytic activity of purified cytoplasmic granules from cytotoxic rat large granular lymphocyte tumors. J Exp Med 1984;160:75–93.[Abstract/Free Full Text]
  17. Podack ER, Konigsberg PJ. Cytolytic T cell granules: isolation, structural, biochemical and functional characterization. J Exp Med 1984;160:695–710.[Abstract/Free Full Text]
  18. Kraut RP, Bose R, Crogoe JR et al. The Na+/CA2+ exchanger regulates cytolysis/perforin-induced increases in intracellular CA2+ and susceptibility to cytolysis. J Immunol 1992;148:2489–2496.[Abstract]
  19. Young JD-E, Hengartner H, Podack ER et al. Purification and characterization of a cytolytic pore-forming protein from granules of cloned lymphocytes with natural killer cell activity. Cell 1986;44:849–859.[Medline]
  20. Craido M, Lindstrom CG, Dennert G. Cytotoxic granules from natural killer cells: specificity of granules and insertion of channels of defined size into target membrane. J Immunol 1985;135:4245–4251.[Abstract]
  21. Sauer H, Pratsch L, Tschopp J et al. Functional size of complement and perforin pores compared by confocal laser scanning microscopy and fluorescence microphotolysis. Acta Biochim Biophys 1991;1063:137–146.
  22. Shi L, Sabine M, Israels S et al. Granzyme B (Gra B) autonomously crosses the cell membrane and perforin initiates apoptosis and Gra B nuclear localization. J Exp Med 1997;185:855–866.[Abstract/Free Full Text]
  23. Froelich CJ, Orth K, Turbov J et al. New paradigm for lymphocyte granule-mediated cytotoxicity. Target cells bind and internalize granzyme B, but an endosomolytic agent is necessary for cytosolic delivery and subsequent apoptosis. J Biol Chem 1996;271:29073–29079.[Abstract/Free Full Text]
  24. Jans DA, Jans P, Briggs LJ et al. Nuclear transport of granzyme B (fragmentin -2). Dependence on perforin in vivo and cytosolic factors in vitro. J Biol Chem 1996;271:30781–30789.[Abstract/Free Full Text]
  25. Moretta A. Molecular mechanisms in cell-mediated cytotoxicity (meeting review). Cell 1997;90:13–18.[Medline]
  26. Murphy ME, Moult J, Bleackley RC et al. Comparative molecular model building of two serine proteinases from cytotoxic T lymphocytes. Proteins 1988;4:190–204.[Medline]
  27. Odake S, Kam CM, Narasimhan L et al. Human and murine cytotoxic T lymphocyte serine proteases: subsite mapping with peptide thioester substrates and inhibition of enzyme activity and cytolysis by isocoumarins. Biochemistry 1991;30:2217–2227.[Medline]
  28. Vaux DL, Haecker G, Strasser A. An evolutionary perspective on apoptosis. Cell 1994;76:777–779.[Medline]
  29. Caputo A, James MN, Powers JC et al. Conversion of the substrate specificity of mouse proteinase granzyme B. Nat Struct Biol 1994;1:364–367.[Medline]
  30. Henkart PA. ICE family proteases: mediators of all apoptotic cell death? Immunity 1996;4:195–201.[Medline]
  31. Martin SJ, Green DR. Protease activation during apoptosis: death by a thousand cuts? Cell 1995;82:349–352.[Medline]
  32. Alnemie ES, Livingston DJ, Nicholson DW et al. Human ICE/CED-3 protease nomenclature. Cell 1996;87:171.[Medline]
  33. Yuan J-Y, Horvitz RH. Genetics mosaic analysis of ced-3 and ced-4, two genes that control programmed cell death in the nematode c. elegans.Dev Biol 1990;138:33–41.[Medline]
  34. Ellis RE, Yuan JY, Horvitz HR. Mechanisms and functions of cell death. Annu Rev Cell Biol 1991;7:663–698.
  35. Ellis HM, Horvitz HR. Genetic control of programmed cell death in nematode C. elegans.Cell 1986;44:817–829.[Medline]
  36. Vaux DL, Weissman IL, Kim SK. Prevention of programmed cell death in Caenorhabditus elegans by human bcl-2. Science 1992;258:1955–1957.[Abstract/Free Full Text]
  37. Hengartner MO, Horvitz HR. C. elegans cell survival gene ced-9 encodes a functioning homolog of the mammalian proto oncogene bcl-2. Cell 1994;76:665–676.[Medline]
  38. Chinnaiyan AM, O’Rourke K, Lane BR et al. Interaction of CED-4 with CED-3 and CED-9: a molecular framework for cell death. Science 1997;275:1122–1126.[Abstract/Free Full Text]
  39. Irmler M, Hofmann K, Vaux D et al. Direct physical interaction between the Caenorhabditus elegans "death proteins" CED-3 and CED-4. FEBS Lett 1997;406:180–190.
  40. Hoffmann K, Bucher P, Tschopp J. The CARD domain: a new apoptotic signalling motif. Trends Biochem Sci 1997;22:155–156.[Medline]
  41. Zou H, Henzel WJ, Liu X et al. Apaf-1, a human protein homologous to c. elegans ced-4, participates in cytochrome c-dependent activation of caspase-3. Cell 1997;90:405–413.[Medline]
  42. Vaux DL. CED-4 - the third horseman of apoptosis (mini reviews). Cell 1997:90:389–390.[Medline]
  43. Darmon AJ, Ehrman N, Caputo A et al. The cytotoxic T cell proteinase granzyme B does not activate interleukin-1B-converting enzyme. J Biol Chem 1994;269:32043–32046.[Abstract/Free Full Text]
  44. Darmon AJ, Nicholson DW, Bleackley RC. Activation of the apoptotic protease CPP32 by cytotoxic T cell-derived granzyme B. Nature 1995;377:446–448.[Medline]
  45. Darmon AJ, Ley TJ, Nicholson DW et al. Cleavage of CPP-32 by granzyme B represents a critical role for granzyme B in the induction of target cell DNA fragmentation. J Biol Chem 1996;271:21709–21712.[Abstract/Free Full Text]
  46. Duan HJ, Orth K, Chinnaiyan AM et al. ICE-LAP6, a novel member of the ICE/Ced-3 gene family, is activated by the cytotoxic T cell protease granzyme B. J Biol Chem 1996;271:16720–16724.[Abstract/Free Full Text]
  47. Scrinivasula SM, Fernandes-Alnemri T, Zangrilli J et al. The Ced-3/interleukin 1-B converting enzyme-like homolog Mch 6 and the lamin-cleaving enzyme Mch2K are substrates for the apoptotic mediator CPP32. J Biol Chem 1996;271:27099–27106.[Abstract/Free Full Text]
  48. Bolding MP, Goncharov TM, Golstev YV et al. Involvement of MACH, a novel MORT/FADD-interacting protease, in Fas/APO-1 and TNF-receptor-induced cell death. Cell 1996;85:803–815.[Medline]
  49. Muzio M, Chinnaiyan AM, Kischkel FC et al. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 1996;85:817–827.[Medline]
  50. Kischkel FC. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins from a death-inducing signaling complex (DISC) with the receptor. EMBO J 1995;14:5579–5588.[Medline]
  51. Nakajima H, Golstein P, Henkart PA. The target cell nucleus is not required for cell-mediated granzyme- or Fas-based cytotoxicity. J Exp Med 1995;181:1905–1909.[Abstract/Free Full Text]
  52. Sarin A, Williams MS, Alexander-Miller MA et al. Target cell lysis by CTL granule exocytosis is independent of ICE/Ced-3 family of proteases. Immunity 1997;6:209–215.[Medline]
  53. Thome M, Schneider P, Hoffman K et al. Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature 1997;386:517–521.[Medline]
  54. Shen Y, Shenk TE. Viruses and apoptosis. Curr Biol 1995;5:105–111.




This Article
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Niederhuber, J. E.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Niederhuber, J. E.

HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS